[go: up one dir, main page]

PT2997033T - Compostos heterocíclicos tricíclicos fundidos como inibidores de vih integrase - Google Patents

Compostos heterocíclicos tricíclicos fundidos como inibidores de vih integrase

Info

Publication number
PT2997033T
PT2997033T PT147981880T PT14798188T PT2997033T PT 2997033 T PT2997033 T PT 2997033T PT 147981880 T PT147981880 T PT 147981880T PT 14798188 T PT14798188 T PT 14798188T PT 2997033 T PT2997033 T PT 2997033T
Authority
PT
Portugal
Prior art keywords
heterocyclic compounds
hiv integrase
integrase inhibitors
tricyclic heterocyclic
fused tricyclic
Prior art date
Application number
PT147981880T
Other languages
English (en)
Inventor
J Coleman Paul
J Hartingh Timothy
T Raheem Izzat
Schreier John
T Sisko John
Wai John
Graham Thomas
Hu Lihong
Peng Xuanjia
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PT2997033T publication Critical patent/PT2997033T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT147981880T 2013-05-17 2014-04-18 Compostos heterocíclicos tricíclicos fundidos como inibidores de vih integrase PT2997033T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361824739P 2013-05-17 2013-05-17

Publications (1)

Publication Number Publication Date
PT2997033T true PT2997033T (pt) 2018-01-25

Family

ID=51897679

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147981880T PT2997033T (pt) 2013-05-17 2014-04-18 Compostos heterocíclicos tricíclicos fundidos como inibidores de vih integrase

Country Status (19)

Country Link
US (1) US9643982B2 (pt)
EP (2) EP2997033B1 (pt)
AR (1) AR096332A1 (pt)
AU (1) AU2014267951A1 (pt)
CY (1) CY1119842T1 (pt)
DK (1) DK2997033T3 (pt)
ES (1) ES2656696T3 (pt)
HK (1) HK1248685A1 (pt)
HR (1) HRP20180081T1 (pt)
HU (1) HUE036384T2 (pt)
LT (1) LT2997033T (pt)
ME (1) ME02977B (pt)
NO (1) NO3058793T3 (pt)
PL (1) PL2997033T3 (pt)
PT (1) PT2997033T (pt)
RS (1) RS56701B1 (pt)
SI (1) SI2997033T1 (pt)
TW (1) TWI656122B (pt)
WO (1) WO2014183532A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3196201B1 (en) 2014-08-22 2021-04-28 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
TWI520963B (zh) * 2014-12-24 2016-02-11 國立清華大學 1,9-二氮萉衍生物及其製法
WO2017113288A1 (en) * 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JP2020500866A (ja) * 2016-12-02 2020-01-16 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Hivインテグラーゼ阻害剤として有用な三環式複素環化合物
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
MA52367A (fr) * 2018-04-27 2021-03-03 Merck Sharp & Dohme Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
AR115455A1 (es) 2018-05-31 2021-01-20 Shionogi & Co Derivado de piridotriazina policíclica
MA52802A (fr) 2018-05-31 2021-04-14 Shionogi & Co Dérivé de pyridone polycyclique
ES2989103T3 (es) 2018-06-05 2024-11-25 Merck Sharp & Dohme Llc Compuestos de heterociclo tricíclico útiles como inhibidores de la integrasa del VIH
US10954234B2 (en) 2018-06-21 2021-03-23 Genentech, Inc. Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
TW202544011A (zh) 2019-03-22 2025-11-16 美商基利科學股份有限公司 橋鍵聯三環胺甲醯吡啶酮化合物及其醫藥用途
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
TWI902729B (zh) 2019-11-28 2025-11-01 日商鹽野義製藥股份有限公司 以組合整合酶阻礙劑及抗hiv藥為特徵之hiv感染症的預防及治療用醫藥
JP7453399B2 (ja) 2020-02-24 2024-03-19 ギリアード サイエンシーズ, インコーポレイテッド Hiv感染症を治療するための四環式化合物及びその使用
KR20230079137A (ko) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
PL4196479T3 (pl) 2021-01-19 2024-03-18 Gilead Sciences, Inc. Podstawione związki pirydotriazynowe i ich zastosowania
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3042894T1 (da) 2001-08-10 2016-11-07 Shionogi & Co Antiviralt middel
SI1441734T1 (sl) 2001-10-26 2007-08-31 Angeletti P Ist Richerche Bio Dihidropirimidin karboksamidni inhibitorji HIV-integraze
UA77454C2 (en) 2001-10-26 2006-12-15 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
ATE370948T1 (de) 2002-01-17 2007-09-15 Merck & Co Inc Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
RU2329265C2 (ru) 2002-12-27 2008-07-20 Институто Ди Ричерке Ди Биолоджиа Молеколаре П.Анджелетти Спа ТЕТРАГИДРО-4Н-ПИРИДО[1,2-а]ПИРИМИДИНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ВИЧ-ИНТЕГРАЗЫ
WO2004062613A2 (en) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
EP1725535A4 (en) * 2004-03-09 2009-11-25 Merck & Co Inc HIV integrase
NZ549449A (en) * 2004-03-09 2009-05-31 Merck & Co Inc HIV Integrase inhibitors
EP1725102A4 (en) * 2004-03-09 2009-04-29 Merck & Co Inc HIV integrase
AU2005221864A1 (en) * 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa HIV integrase inhibitors
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7173022B2 (en) 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
CN101146811B (zh) 2005-03-31 2012-01-11 P.安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
US7494984B2 (en) 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
WO2007059125A2 (en) 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7902182B2 (en) 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
US8039458B2 (en) 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
US7897593B2 (en) 2006-05-30 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
KR20120087916A (ko) 2009-10-13 2012-08-07 엘랑코 애니멀 헬쓰 아일랜드 리미티드 마크로시클릭 인테그라제 억제제
AU2011221037A1 (en) * 2010-02-26 2012-09-06 Japan Tobacco Inc. 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivative and use of same as HIV integrase inhibitor
JP5739517B2 (ja) 2010-04-02 2015-06-24 ヤンセン・アールアンドデイ・アイルランド 大環状インテグラーゼ阻害剤

Also Published As

Publication number Publication date
HUE036384T2 (hu) 2018-07-30
US20160108059A1 (en) 2016-04-21
US9643982B2 (en) 2017-05-09
ES2656696T3 (es) 2018-02-28
EP3330272B1 (en) 2021-02-17
CY1119842T1 (el) 2018-06-27
ME02977B (me) 2018-10-20
EP2997033A4 (en) 2016-10-26
TW201524978A (zh) 2015-07-01
HK1248685A1 (en) 2018-10-19
SI2997033T1 (en) 2018-04-30
NO3058793T3 (pt) 2018-03-17
AU2014267951A1 (en) 2015-11-19
EP3330272A1 (en) 2018-06-06
AR096332A1 (es) 2015-12-23
LT2997033T (lt) 2018-02-12
RS56701B1 (sr) 2018-03-30
PL2997033T3 (pl) 2018-04-30
EP2997033A1 (en) 2016-03-23
HRP20180081T1 (hr) 2018-02-23
EP2997033B1 (en) 2017-11-15
DK2997033T3 (da) 2018-01-29
WO2014183532A1 (en) 2014-11-20
TWI656122B (zh) 2019-04-11

Similar Documents

Publication Publication Date Title
EP3008044A4 (en) Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
ME02977B (me) Fuzionisana triciklicna heterociklicna jedinjenja као inhibiтori hiv integraze
ZA201601708B (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors
IL239457A0 (en) Novel heterocyclic compounds as bromodomain inhibitors
EP3083641A4 (en) Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
SG11201605654QA (en) Fused heterocyclic compound
IL266908A (en) Heterocyclic tetracyclic compounds for use as hiv integrase inhibitors
IL265496A (en) bace1 inhibitors
ZA201508396B (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
IL245379A0 (en) Heterocyclic n-acylamino compounds
IL245301A0 (en) New heterocyclic compounds
IL254424A0 (en) Disubstituted heterocyclic tricyclic compounds
ZA201508864B (en) Substituted heterocyclic compounds as crac modulators
IL240612A0 (en) Tricyclic heterocycles as anti-cancer agents
PT3063139T (pt) Composto heterocíclico
IL244347A0 (en) n-acylamino heterocyclic compounds
IL241962B (en) Heterocyclic acetamide compound
GB201322752D0 (en) Novel ferrocenyl compounds
GB201310126D0 (en) Novel pyrrole derivatives
GB201309960D0 (en) Novel pyrrole derivatives
GB201309935D0 (en) Novel pyrrole derivatives
GB201314960D0 (en) Heterocyclic derivatives
GB201300306D0 (en) Heterocyclic derivatives
GB201300649D0 (en) Cyclization
GB201309934D0 (en) Novel pyrrole derivatives